Text Size
Trial record 14 of 212 for:    driving
Previous Study | Return to List | Next Study

Expectation of Driving Performance in Young Adults With ADHD Assessed by Driving Simulator and Seat Pressure Mapping (no)

This study is not yet open for participant recruitment.
Verified August 2011 by Meir Medical Center
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01179386
First received: August 9, 2010
Last updated: August 27, 2011
Last verified: August 2011
History of Changes
  Purpose

Adolescents suffering of ADHD may have impaired driving performance. The investigators would like to check the differences in driving performance in young adults(aged: 15-18 years) with ADHD by driving simulator and seat pressure mapping with and without methylphenidate medication.


Condition
Attention Deficit Hyperactivity Disorder

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Expectation of Driving Performance in Young Adults With ADHD Assessed by Driving Simulator and Seat Pressure Mapping

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Meir Medical Center:

Estimated Enrollment: 60
Study Start Date: November 2011
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
methylphenidate
30 adolescents who are treated with Methylphenidate will perform the driving simulator and seat pressure mapping tests, in 2 different days : 1. with their regular methylphenidate medication and 2: without the methylphenidate medication after a 4 days washout period. Results will be recorded and statistical test will be performed.
no medication
30 adolescents : control group , not suffering from ADHD and without methylphenidate medication will perform the driving simulator and seat pressure mapping tests. Results will be recorded and statistical test will be performed.

Detailed Description:

Adolescents with ADHD who are treated with one of the methylphenidate medication that is in use in Israel(Ritalin,Ritalin SR,Concerta,Ritalin LA)will be tested by driving simulator and seat pressure mapping by 2 stages: 1.when they are taking the medication that they are taking every day to control ADHD and: 2. without medication ( after 4 day washout period).

  Eligibility

Ages Eligible for Study:   15 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

30 adolescents aged 15-18 years ,diagnosed as suffering from ADHD and being treated with a methylphenidate medication that is used in Israel 30 adolescents aged 15-18, without ADHD will the control group

Criteria

Inclusion Criteria:

  • age 15-18 years Suffering from ADHD treated by methylphenidate before receiving driving license

Exclusion Criteria:

  • any other neurological or psychiatric problem under treatment or investment adolescents who have driving license
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01179386

Contacts
Contact: Dr Cohen Herman, MD 972-3-9398200 hermanc@post.tau.ac.il

Locations
Israel
Cohen Herman Avner
Petah-Tikva, Israel
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: cohen he avner, md sherute briut clalit
Study Director: razon nava, Dr Tel Aviv University
  More Information

Publications:

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01179386     History of Changes
Other Study ID Numbers: hermanadhd
Study First Received: August 9, 2010
Last Updated: August 27, 2011
Health Authority: Israel: Ethics Commission

Keywords provided by Meir Medical Center:
methylphenidate
ADHD
driving
 simulator
pressure
adolescent

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Methylphenidate
 Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013